SELECT PUBLICATIONS


SELECT PUBLICATIONS

A Phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma. NCT02420821

Antonarakis ES et al. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium 2015;Abstract 138.

Antonarakis ES et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38. Abstract

Ascierto ML et al. Transcriptional signatures associated with lack of response to anti-PD-1 therapy in patients with renal cell carcinoma. Proc AACR 2015;Abstract 1312/11.

Fizazi K et al. Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). Genitourinary Cancers Symposium 2015;Abstract 169.

Fong L et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106(11). Abstract

Hammers HJ et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Proc ASCO 2014;Abstract 4504.

Hoffman-Censits JH et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). Genitourinary Cancers Symposium 2016;Abstract 355.

McDermott DF et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a Phase Ia study. J Clin Oncol 2016;[Epub ahead of print]. Abstract

Mejri N et al. Status of HER2 overexpression in muscle invasive urothelial bladder carcinoma: Report of 21 cases. Urol Ann 2014;6(1):63-7. Abstract

Motzer RJ et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. Abstract

Motzer R et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc ASCO 2015;Abstract 4506.

Oude Elferink P, Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. Ther Adv Urol 2014;6(1):25-33. Abstract

Penson D et al. A multicenter Phase 2 study of enzalutamide versus bicalutamide in men with nonmetastatic or metastatic castration-resistant prostate cancer: The STRIVE trial. Proc AUA 2015;Abstract LBA10.

Petrylak D et al. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Proc ASCO 2015;Abstract 4501.

Plimack ER et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. Proc ASCO 2015;Abstract 4502.

Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515(7528):558-62. Abstract

Rosenberg J et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). Proc ECCO 2015;Abstract 21LBA.

Taplin ME et al. Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV) — Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer expressing AR-V7 splice variant. Proc ASCO 2015;Abstract TPS5069.